Berra, Edurne

Physiopathology of the Hypoxia signalling pathway (HypoxiPATH)

Berra, Edurne
Berra, Edurne
Physiopathology of the Hypoxia signalling pathway (HypoxiPATH)


Parque Tecnológico de Bizkaia-Ed.801A

Phone number
Hypoxia, HIFs, PHDs, DUBs, prostate cancer
Brief description of the research:

Our research focuses on two main lines of research. We study the role of posttranslational modifications (PTM) in the response to hypoxia and in particular, in the regulation of the oxygen sensors, including the prolyl-hydroxylases (PHDs), and their major targets, the hypoxia-induced transcription factors (HIFs). In this sense, the group is currently focused on the understanding of the role of the ubiquitin-mediated modifications. In addition, we aim to understand the role of PHDs and HIFs in prostate cancer cell respiration and therefore, in the progression and aggressiveness of prostate cancer.

5 selected publications:
  1. Irigoyen M, García-Ruiz JC, Berra E (2017) The hypoxia signalling pathway in haematological malignancies. Oncotarget 8, 36832-36844.

  2. Iriondo O, Rábano M, Domenici G, Carlevaris O, López-Ruiz JA, Zabalza I, Berra E, Vivanco MdM (2015) Distinct breast cancer stem/progenitor cell populations require either HIF1 loss PHD3 to expand under hypoxic conditions Oncotarget 6, 31721-31739.

  3. Núñez-O'Mara A, Gerpe-Pita A, Pozo S, Carlevaris O, Urzelai B, Lopitz-Otsoa F, Rodriguez MS, Berra E. (2015) PHD3-SUMO conjugation optimizes HIF1 repression independently of PHD3 catalytic activity J.Cell Sci. 128 (1), 40-49.

  4. Nuñez-O´Mara A & Berra E (2013) Deciphering the emerging role of SUMO conjugation in the Hypoxia-signalling cascade Biol. Chem. 394, 459-469.

  5. Oliveira H, Pérez-Andrés E, Thevenot J, Sandre O, Lecommandoux S, Berra E (*) senior authorship (2013) Magnetic field triggered drug release from polymersomes for cancer therapeutics J. Control. Release 169, 165-170.